Robert Posnick, MD
Dermatology · Nashua, NHNPI 1497866388
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $737,335 of the $951,469 with a category attached, or 77.5%. 31 manufacturers reported payments, led by Amgen at 33.4% of the total. Among dermatology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,351 payments — averaging $404.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$318K
- AbbVie$137K
- Sun Pharmaceutical Industries Inc.$93K
- Incyte Corporation$63K
- Pfizer$56K
- E.r. Squibb & Sons, L.L.C.$51K
- plus $233K from 25 others
Across 12 payments — averaging $3334.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$28K
- AbbVie$12K
What the payments were for
- Consulting fees$50,5855%
- Speaking & faculty fees$737,33577%
- Travel & lodging$93,07410%
- Food & beverage$69,1627%
- Education$1,3140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 481 | $317,702 |
| AbbVie | 373 | $137,461 |
| Sun Pharmaceutical Industries Inc. | 131 | $93,268 |
| Incyte Corporation | 126 | $62,676 |
| Pfizer | 111 | $56,078 |
| E.r. Squibb & Sons, L.L.C. | 90 | $51,003 |
| UCB, Inc. | 179 | $48,365 |
| Galderma Laboratories, L.p. | 65 | $46,641 |
| Bristol Myers Squibb | 65 | $35,917 |
| Janssen Scientific Affairs, LLC | 39 | $32,136 |
| Novartis | 107 | $31,645 |
| Sanofi | 88 | $12,093 |
| Lilly USA, LLC | 72 | $10,075 |
| LEO Pharma Inc. | 179 | $3,921 |
| Johnson & Johnson | 102 | $2,675 |
| Dermavant Sciences, Inc. | 16 | $1,783 |
| Boehringer Ingelheim | 4 | $1,774 |
| Botanix SB Inc | 2 | $1,674 |
| Arcutis Biotherapeutics, Inc. | 37 | $1,352 |
| Sanofi-aventis U.S. LLC | 15 | $1,228 |
| Regeneron Healthcare Solutions, Inc. | 19 | $685 |
| Organon | 10 | $332 |
| Mayne Pharma Commercial LLC | 9 | $269 |
| VYNE Pharmaceuticals Inc. | 7 | $245 |
| Genentech USA, Inc. | 9 | $212 |
| Helsinn Therapeutics (U.S.), Inc. | 8 | $103 |
| Regeneron | 2 | $68 |
| Dermira, Inc. | 2 | $38 |
| Biofrontera Inc. | 1 | $19 |
| Strata Skin Sciences, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$951,469 in reported general payments places this provider in the 95th percentile of 75 dermatology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 47 | $252,294 |
| Dupixent PenDupilumab | 33 | $122,604 |
| Cosentyx Unoready PenSecukinumab | 12 | $109,126 |
| Dupixent SyringeDupilumab | 13 | $47,295 |
| OpzeluraRuxolitinib Phosphate | 20 | $41,737 |
| Halobetasol Propionate | 57 | $3,061 |
| Metronidazole | 63 | $2,896 |
| Azelaic Acid | 12 | $1,793 |
| CiclopiroxCiclopirox Olamine | 65 | $1,690 |
| Tretinoin | 16 | $1,480 |
| Betamethasone Dipropionate | 44 | $1,345 |
| Clobetasol Propionate | 17 | $1,088 |
| Ketoconazole | 52 | $952 |
| Doxycycline Monohydrate | 22 | $854 |
| Triamcinolone Acetonide | 86 | $814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $317,702 | $252,29447 claims |
| Incyte CorporationOpzelura | $62,676 | $41,73720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 dermatology providers in New Hampshire.
Other dermatology in Nashua
- David PosnickNashua$203K
- Michael LichterNashua$53K
- Christopher MancusoNashua$22K
- Stephen MoyerNashua$3K
- Rana AbdatNashua$720
- Abdulaziz AlomranNashua$369
- Elizabeth LesterNashua$78
- Abel JarellPortsmouth$2.3M
- Yulianna RussakLebanon$170K
- Peter JenkinManchester$117K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.